Literature DB >> 8360932

Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia.

J Y Li1, P R Taylor, B Li, S Dawsey, G Q Wang, A G Ershow, W Guo, S F Liu, C S Yang, Q Shen.   

Abstract

BACKGROUND: A number of vitamins and minerals have been shown to influence carcinogenesis in experimental animals. In humans, epidemiologic evidence suggests that intake of fruits and vegetables may reduce risk of esophageal and other cancers. Vitamins and minerals in these foods may contribute to the reduced cancer risk. The people of Linxian, China, have persistently low intake of multiple nutrients and exhibit one of the world's highest rates of esophageal/gastric cardia cancer, with an exceptionally high risk of esophageal dysplasia.
PURPOSE: To determine whether supplementation with multiple vitamins and minerals may reduce esophageal/gastric cardia cancer among persons with esophageal dysplasia, we conducted a 6-year prospective intervention trial in Linxian.
METHODS: Mortality and cancer incidence were ascertained from May 1985 through May 1991 for 3318 persons with cytologic evidence of esophageal dysplasia who were randomly assigned to receive, throughout that period, daily supplementation with 14 vitamins and 12 minerals or placebo. Doses were typically two to three times U.S. Recommended Daily Allowances. Compliance was assessed by counting unused pills monthly for all trial participants and by assaying nutrient levels in blood collected from samples of individuals randomly selected without replacement every 3 months throughout the trial. Cancers were identified through routine surveillance and by special cytology and endoscopy screenings after 2 1/2 years and 6 years.
RESULTS: A total of 324 deaths occurred during the 6-year intervention period; 167 occurred in the control (placebo) group and 157 occurred in the supplement group. Cancer was the leading cause of death (54% of all deaths); 18% were due to cerebrovascular diseases and 29% to other causes. Cumulative esophageal/gastric cardia death rates were 8% lower (relative risk [RR] = 0.92; 95% confidence interval [CI] = 0.67-1.28) among individuals receiving supplements rather than placebo, a nonsignificant (P > .10) difference. Risk of total mortality was 7% lower (RR = 0.93; 95% CI = 0.75-1.16; P > .10), total cancer 4% lower (RR = 0.96; 95% CI = 0.71-1.29; P > .10), cerebrovascular disease 38% lower (RR = 0.62; 95% CI = 0.37-1.06; P = .08), and other diseases 12% higher (RR = 1.12; 95% CI = 0.74-1.69; P > .10) among the treated group. Cumulative cancer incidence rates were nearly the same in the two groups.
CONCLUSIONS: No substantial short-term beneficial effect on incidence or mortality for this type of cancer occurred following daily supplementation with multiple vitamins and minerals among adults with precancerous lesions of the esophagus. IMPLICATIONS: Although no statistically significant short-term benefits were observed, longer follow-up should be more informative about the effectiveness of this 6-year supplementation on cancer and other diseases among individuals with esophageal dysplasia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8360932     DOI: 10.1093/jnci/85.18.1492

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  73 in total

1.  Dichlorodiphenyltrichloroethane and risk of hepatocellular carcinoma.

Authors:  E Christina Persson; Barry I Graubard; Alison A Evans; W Thomas London; Jean-Philippe Weber; Alain LeBlanc; Gang Chen; Wenyao Lin; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2012-03-15       Impact factor: 7.396

2.  Dietary supplements and cancer prevention: balancing potential benefits against proven harms.

Authors:  María Elena Martínez; Elizabeth T Jacobs; John A Baron; James R Marshall; Tim Byers
Journal:  J Natl Cancer Inst       Date:  2012-04-25       Impact factor: 13.506

3.  Chemopreventive effects of early-stage and late-stage supplementation of vitamin E and selenium on esophageal carcinogenesis in rats maintained on a low vitamin E/selenium diet.

Authors:  Hui Yang; Jin Fang; Xudong Jia; Chi Han; Xiaoxin Chen; Chung S Yang; Ning Li
Journal:  Carcinogenesis       Date:  2010-12-24       Impact factor: 4.944

4.  Reduction of cancer mortality and incidence by selenium supplementation.

Authors:  G F Combs; L C Clark; B W Turnbull
Journal:  Med Klin (Munich)       Date:  1997-09-15

5.  Suppressive effects of lycopene and β-carotene on the viability of the human esophageal squamous carcinoma cell line EC109.

Authors:  Nguyen Ba Ngoc; Pin Lv; Wen-En Zhao
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

6.  Imbalance in Protein Thiol Redox Regulation and Cancer-Preventive Efficacy of Selenium.

Authors:  Rayudu Gopalakrishna; Usha Gundimeda; Sarah Zhou; Kristen Zung; Kaitlyn Forell; Arne Holmgren
Journal:  React Oxyg Species (Apex)       Date:  2016-05-25

Review 7.  Nutrition and esophageal cancer.

Authors:  K K Cheng; N E Day
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

Review 8.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

9.  The randomized Linxian Dysplasia Nutrition Intervention Trial after 26 years of follow-up: no effect of multivitamin supplementation on mortality.

Authors:  Jian-Bing Wang; Christian C Abnet; Jin-Hu Fan; You-Lin Qiao; Philip R Taylor
Journal:  JAMA Intern Med       Date:  2013-07-08       Impact factor: 21.873

10.  Plasma levels of beta-carotene are inversely correlated with circulating neutrophil counts in young male cigarette smokers.

Authors:  V L Van Antwerpen; A J Theron; G A Richards; C A Van der Merwe; E Viljoen; R Van der Walt; R Anderson
Journal:  Inflammation       Date:  1995-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.